GlassScriptPhysician profile
Jeffrey E Hartman
NPI 1578630687
$2,388.56
in general payments reported to CMS, 2019-2025
15 companies · $75.71 in 2025
The $75.71 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $421 · 2021: $199 · 2022: $570 · 2023: $269 · 2024: $214 · 2025: $75.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466 · Education: $93.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.02 |
| Education | $93.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $853.99 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.18 | 2022-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $260.54 | 2019-2023 | |
| Corcept Therapeutics | $205.58 | 2019-2024 | Korlym |
| Lilly USA, LLC | $189.15 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $125.45 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $124.99 | 2022 | |
| Medtronic, INC. | $67.31 | 2021-2023 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $46.87 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $43.44 | 2025 | |
| Merck Sharp & Dohme LLC | $32.49 | 2019 | |
| Recordati_rare_diseases_inc. | $31.70 | 2023 | Isturisa, Signifor Lar |
| Abbott Laboratories | $18.91 | 2021 | |
| Abbvie INC. | $18.11 | 2023 | |
| Dexcom, INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.